AZ, Innate's checkpoint inhibitor monalizumab flunks phase 3...

AstraZeneca has abandoned a phase 3 trial of its experimental immuno-oncology candidate monalizumab in head and neck cancer, after an interim analysis suggested it was unlikely to show a be